Fate Therapeutics, Inc.
(NASDAQ : FATE)

( )
FATE PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -10.62%131.220.0%$1316.56m
OCGNOcugen, Inc. 8.96%10.460.0%$1254.01m
NVAXNovavax, Inc. -10.87%183.6192.9%$721.22m
AMGNAmgen, Inc. -0.78%223.941.3%$548.96m
VRTXVertex Pharmaceuticals, Inc. -1.71%208.441.9%$518.86m
REGNRegeneron Pharmaceuticals, Inc. -1.79%446.732.7%$503.19m
GILDGilead Sciences, Inc. -0.41%62.751.0%$480.06m
ILMNIllumina, Inc. -5.58%416.413.5%$476.48m
ALXNAlexion Pharmaceuticals, Inc. -1.45%148.192.0%$341.53m
BIIBBiogen, Inc. -1.20%266.601.7%$320.42m
BNGOBionano Genomics, Inc. -9.81%8.550.0%$302.38m
CRSPCRISPR Therapeutics AG -8.24%119.080.6%$282.94m
EXASEXACT Sciences Corp. -7.20%126.5718.4%$236.04m
SGENSeagen Inc. -3.76%147.935.8%$209.02m
PACBPacific Biosciences of California, Inc. -9.83%30.977.2%$163.85m

Company Profile

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.